Γερμανία - Γερμανικά - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

franz ziegler - hepar sulfuris (pot.-angaben), pyrogenium-nosode (pot.-angaben), acidum silicicum (pot.-angaben), lycosa (pot.-angaben) - flüssige verdünnung zur injektion - hepar sulfuris (pot.-angaben) 1.g; pyrogenium-nosode (pot.-angaben) 10.g; acidum silicicum (pot.-angaben) 1.g; lycosa (pot.-angaben) 1.g

Γερμανία - Γερμανικά - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

franz ziegler (3305148) - injektion subkutan; injektion subkutan; injektion subkutan; injektion subkutan; injektion subkutan; injektion subkutan; injektion subkutan; acidum silicicum (pot.-angaben); hepar sulfuris (pot.-angaben); lycosa (pot.-angaben); pyrogenium-nosode (pot.-angaben) - flüssige verdünnung zur injektion - injektion subkutan (hund) - -; injektion subkutan (katze) - -; injektion subkutan (pferd) - -; injektion subkutan (rind) - -; injektion subkutan (schaf) - -; injektion subkutan (schwein) - -; injektion subkutan (ziege) - -; acidum silicicum (pot.-angaben) (01218) 1 gramm; hepar sulfuris (pot.-angaben) (01448) 1 gramm; lycosa (pot.-angaben) (02481) 1 gramm; pyrogenium-nosode (pot.-angaben) (06186) 1 gramm - ziege; rind; katze; pferd; schaf; hund; schwein

Ισπανία - Ισπανικά - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

hospira invicta s.a. - heparina sodica - soluciÓn inyectable - 1.000 ui/ml inyectable 5 ml - heparina sodica 1000 ui - heparina

Ισπανία - Ισπανικά - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

hospira invicta s.a. - heparina sodica - soluciÓn inyectable - 5.000 ui/ml inyectable 5 ml - heparina sodica 5000 ui - heparina

Ισπανία - Ισπανικά - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios farmaceuticos rovi s.a. - heparina sodica - soluciÓn inyectable - 5.000 ui/ml inyectable 5 ml - heparina sodica 5000 ui - heparina

Ισπανία - Ισπανικά - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios farmaceuticos rovi s.a. - heparina sodica - soluciÓn inyectable - 1.000 ui/ml inyectable 5 ml - heparina sodica 1000 ui - heparina

Ισπανία - Ισπανικά - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios reig jofre, s.a. - heparina sodica - soluciÓn inyectable - 1.000 ui/ml inyectable 5 ml - heparina sodica 1000 ui - heparina

Ισπανία - Ισπανικά - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios reig jofre, s.a. - heparina sodica - soluciÓn inyectable - 5.000 ui/ml inyectable 5 ml - heparina sodica 5000 ui - heparina

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

general injectables & vaccines, inc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 1000 [usp'u] in 1 ml - heparin sodium injection is indicated for: - prophylaxis and treatment of venous thrombosis and pulmonary embolism - prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease - atrial fibrillation with embolization - treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) - prevention of clotting in arterial and cardiac surgery - prophylaxis and treatment of peripheral arterial embolism - anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures the use of heparin sodium is contraindicated in patients with the following conditions: - history of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see warnings and precautions (5.3)] - known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see adverse reactions (6.1)] - in whom su

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 1000 [usp'u] in 1 ml - heparin sodium injection, usp is indicated for: anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see dosage and administration ); prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism. heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures. heparin sodium should not be used in patients with the following conditions: severe thrombocytopenia; when suitable blood coagulation tests, e.g., the whole